Back to Search Start Over

Comparisons of Colistin-Induced Nephrotoxicity Between Two Different Formulations of Colistin in Critically Ill Patients: A Retrospective Cohort Study

Authors :
David Hung-Tsang Yen
Szu Yuan Li
Sheng-Wei Pan
Yuh Min Chen
Fu Der Wang
Yi Tzu Lee
Kuang Yao Yang
Jia Yih Feng
Source :
Antimicrobial Resistance and Infection Control, Antimicrobial Resistance and Infection Control, Vol 10, Iss 1, Pp 1-12 (2021)
Publication Year :
2021
Publisher :
Research Square Platform LLC, 2021.

Abstract

Background Colistin is widely used in the treatment of nosocomial infections caused by carbapenem-resistant gram-negative bacilli (CR-GNB). Colistin-induced nephrotoxicity is one of the major adverse reactions during colistin treatment. Comparisons of colistin-induced nephrotoxicity between different formulations of colistin are rarely reported. Methods In this retrospective cohort study, we enrolled intensive care unit–admitted patients if they had culture isolates of CR-GNB and underwent intravenous treatment with colistin. The occurrence of acute kidney injury (AKI) during intravenous treatment with colistin was recorded. The occurrence of colistin-induced nephrotoxicity was compared between two formulations of colistin, Locolin®, and Colimycin®. Treatment outcomes associated with the occurrence of colistin-induced nephrotoxicity were also investigated. Results Among 195 patients, 95 who were treated with Locolin® and 100 who were treated with Colimycin® were included for analysis. Patients treated with Locolin® had a higher rate of occurrence of stage 2 (46.3% vs. 32%, p = 0.040) and stage 3 (29.5% vs. 13%, p = 0.005) AKI than did those treated with Colimycin®. In multivariate analysis, the presence of septic shock (adjusted odds ratio [aOR] 2.17, 95% confidence interval [CI] 1.10–4.26) and inappropriate colistin dosage (aOR 2.52, 95% CI 1.00–6.33) were clinical factors associated with colistin-induced nephrotoxicity. Treatment with Colimycin® was an independent factor associated with a lower risk of colistin-induced nephrotoxicity (aOR 0.37, 95% CI 0.18–0.77). The mortality rate was comparable between patients with and without colistin-induced nephrotoxicity. Conclusions The risk of colistin-induced nephrotoxicity significantly varied in different formulations of colistin in critically ill patients. Colistin-induced nephrotoxicity was not associated with increased mortality rate.

Details

Database :
OpenAIRE
Journal :
Antimicrobial Resistance and Infection Control, Antimicrobial Resistance and Infection Control, Vol 10, Iss 1, Pp 1-12 (2021)
Accession number :
edsair.doi.dedup.....e5922da9cd8f4ace4ffb8a01bd4d1ac7